Kiniksa Pharmaceuticals
KNSA
189 hedge funds and large institutions have $1.1B invested in Kiniksa Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 65 increasing their positions, 63 reducing their positions, and 33 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
45% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 33
24% more capital invested
Capital invested by funds: $889M → $1.1B (+$213M)
7% more funds holding
Funds holding: 176 → 189 (+13)
3% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 63
1.18% less ownership
Funds ownership: 95.32% → 94.14% (-1.2%)
77% less call options, than puts
Call options by funds: $8.22M | Put options by funds: $36.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$18.7M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$17.1M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$16.6M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$13.4M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$69.5M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$21.9M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$17M |
| 4 |
State Street
Boston,
Massachusetts
|
-$16.2M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$11.6M |
KNSA Hedge Fund Activity: Q2 2025 in Review
189 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2025, worth a combined $1.1B — up 24% from $889M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new KNSA positions and 33 closed out — a net gain of 15 holders — while 65 added to existing stakes and 63 trimmed.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $18.7M. The largest seller was BlackRock, cutting an estimated $69.5M.
- 189 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2025, up from 176 in Q1 2025.
- Funds reported $1.1B of Kiniksa Pharmaceuticals stock for Q2 2025, up 24% quarter-over-quarter.
- 48 funds opened new Kiniksa Pharmaceuticals positions in Q2 2025 and 33 closed out, a net change of +15 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2025 was Arrowstreet Capital, an estimated $18.7M added.
- The largest Kiniksa Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $69.5M sold.
Based on aggregated 13F filings for Q2 2025.